Portuguese Scientist Joins Nobel Prize Committee: What This Means for Portugal's Global Standing

A dual-national scientist with roots in Portugal has been appointed to one of the world's most influential scientific gatekeeping roles: the Nobel Committee for Physiology or Medicine. Gonçalo Castelo-Branco, a professor at Stockholm's Karolinska Institutet, will help shape the shortlist of candidates for the 2026 Nobel Prize in the life sciences, a position that puts him at the center of global medical recognition.

Why This Matters:

• First Portuguese national known to serve on the Nobel Medicine Committee, marking a milestone for Portugal's scientific representation on the global stage.

• Castelo-Branco's research on multiple sclerosis and demyelinating diseases could influence future prize priorities in neuroscience and regenerative medicine.

• The appointment reflects growing international recognition of Portuguese-trained scientists working abroad, potentially boosting research funding and collaboration opportunities for institutions in Portugal.

• His tenure runs March to October 2026, covering the critical evaluation period before the prize announcement in early October.

Who Is Gonçalo Castelo-Branco?

Born in Cantanhede, Portugal, in 1976, Castelo-Branco earned his undergraduate degree in biochemistry from the Universidade de Coimbra in 1999 before moving to Sweden for doctoral studies. He completed his PhD at the Karolinska Institutet in 2005, followed by postdoctoral fellowships at the same institution and at Cambridge University's Gurdon Institute. In 2012, he established his own research group at Karolinska, where he now holds the title of Professor of Glial Cell Biology in the Department of Medical Biochemistry and Biophysics.

His trajectory mirrors a broader trend among Portuguese scientists: training at home, excelling abroad, and maintaining ties to their homeland while building international careers. Castelo-Branco holds both Portuguese and Swedish citizenship, a dual identity that reflects decades of cross-border academic mobility within Europe.

His scientific focus centers on oligodendroglia—specialized brain cells that produce the myelin sheath insulating nerve fibers. When these cells malfunction, diseases like multiple sclerosis (MS) result, causing progressive neurological damage. Castelo-Branco's lab uses cutting-edge techniques, including single-cell genomics and CRISPR-based screens, to map how these cells change in disease states and how they might be coaxed to repair damaged myelin.

Decoding the Committee's Role

The Nobel Committee for Physiology or Medicine operates as the first filter in the prize selection process, but its influence should not be overstated. The committee comprises 5 permanent members elected for three-year terms, plus 10 associated members appointed annually from March to October—the slot Castelo-Branco now fills. The Secretary-General of the Nobel Assembly also participates.

Every year, the committee dispatches invitations to thousands of scientists worldwide, soliciting nominations. Between 200 to 300 nominations typically arrive, which the committee then scrutinizes over several months. Members convene regularly to debate the merits of each candidate, consulting external experts and reviewing scientific literature. By late summer, they distill this pool into a shortlist of finalists, which is forwarded to the Nobel Assembly.

Here's where the structure diverges from public perception: the final decision rests not with the committee but with the Nobel Assembly at Karolinska Institutet, a body of 50 professors from across the medical faculty. The Assembly meets on the first Monday of October to vote on the winner. While the committee's recommendations carry substantial weight—its members are, after all, experts tasked with deep analysis—the Assembly retains the authority to diverge from those recommendations entirely. This two-tier system ensures broader collegial oversight and reduces the risk of narrow biases shaping the prize.

What This Means for Portuguese Science

Castelo-Branco's appointment is historically significant for Portugal. Available records indicate no previous Portuguese national has served on the Nobel Medicine Committee, despite Portugal producing one Nobel laureate in the field: Egas Moniz, who won in 1949 for developing the prefrontal leucotomy (a procedure later discredited, yet recognized at the time for its clinical boldness).

The gap between laureates and committee membership reflects Portugal's evolving scientific standing. For much of the 20th century, Portuguese research institutions lacked the international visibility and funding of peers in Germany, the United Kingdom, or Scandinavia. That has changed over the past two decades, driven by EU research funding, improved doctoral programs, and the diaspora of Portuguese scientists who, like Castelo-Branco, earn recognition abroad and maintain collaborative networks with institutions back home.

His presence on the committee could have practical ripple effects for researchers in Portugal:

• Enhanced visibility for collaborative projects involving Portuguese institutions, particularly in neuroscience and regenerative medicine.

• Stronger networks between Portuguese universities and the Karolinska Institutet, historically one of Europe's top medical research centers.

• Potential mentorship pathways for early-career Portuguese scientists seeking postdoctoral positions or fellowship funding in Sweden.

• Increased credibility for Portuguese grant applications to European Research Council (ERC) programs, where Castelo-Branco himself has secured multiple awards, including Consolidator (2015), Advanced (2023), and Proof of Concept (2025) grants.

Glial Cells and the Multiple Sclerosis Puzzle

Castelo-Branco's research domain—glial cell biology—has emerged as one of the hottest areas in neuroscience over the past decade. For years, neuroscience focused overwhelmingly on neurons, the electrically excitable cells that transmit signals. Glial cells were dismissed as mere "glue" (the literal meaning of glia in Greek), passively supporting neuronal function. That view has collapsed under the weight of evidence showing glial cells actively regulate brain development, synaptic plasticity, immune responses, and disease progression.

Among glial subtypes, oligodendrocytes are Castelo-Branco's specialty. These cells wrap nerve fibers in myelin, a fatty insulation that speeds up electrical signals. In multiple sclerosis, the immune system mistakenly attacks myelin, leading to nerve damage, mobility problems, cognitive decline, and, in severe cases, paralysis. Approximately 2.8 million people worldwide live with MS, with prevalence highest in northern Europe—a demographic reality that has driven substantial research funding in Scandinavia.

Castelo-Branco's team has made several breakthrough discoveries:

• Identifying disease-specific oligodendrocyte states in both mouse models and human MS patient brains, challenging the assumption that all oligodendrocytes respond uniformly to neuroinflammation.

• Demonstrating that oligodendrocytes are epigenetically primed for immune gene activation, meaning their DNA is already "bookmarked" to rapidly turn on inflammatory genes when triggered—a finding with implications for early intervention therapies.

• Revealing that oligodendrocytes play a larger role in MS progression than previously believed, shifting research focus from purely immune-targeted therapies to strategies that protect or regenerate oligodendrocytes themselves.

These insights have positioned Castelo-Branco as a candidate for future Nobel recognition in his own right, though committee members are typically barred from nomination during their tenure.

The Prize and Its Value

The Nobel Prize in Physiology or Medicine remains one of the world's most prestigious scientific honors, established in 1895 by Alfred Nobel, the Swedish chemist and industrialist who invented dynamite. First awarded in 1901, the prize comes with a gold medal, a diploma, and a cash award currently set at 11 M Swedish kronor (approximately €950,000)—a sum that can be life-changing for laureates from less wealthy countries or those working in underfunded fields.

The prize's selection process is shrouded in secrecy, with all nomination and deliberation records sealed for 50 years to protect the integrity of evaluations and prevent lobbying. This opacity has sparked occasional controversy—some laureates have been recognized decades after their key discoveries, while others have been omitted due to the three-person limit per prize or the prohibition on posthumous awards (with rare exceptions for those who die between the announcement and the December ceremony).

A Moment of National Pride

For residents in Portugal, Castelo-Branco's appointment offers a rare moment of recognition in a field where Portuguese contributions often go unnoticed internationally. While Portugal has excelled in literature (José Saramago won the Nobel Prize in Literature in 1998) and produced notable figures in global diplomacy, its presence in the upper echelons of biomedical science has been more modest.

That may be changing. Portuguese universities have steadily climbed international rankings, and the country's biotech sector has attracted growing investment, particularly in Porto and Lisbon. Castelo-Branco's trajectory—educated in Coimbra, flourishing in Stockholm, now serving on the Nobel Committee—illustrates the value of international scientific exchange and the importance of retaining connections with diaspora researchers who can amplify Portugal's reputation abroad.

His tenure on the committee will conclude in October, but the symbolic impact endures: a scientist born in a small Portuguese town now helps decide who receives the world's most coveted prize in medicine.